Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 90. (Canceled)

91. (Currently Amended) A method of enhancing a CTL immune response in an animal which comprises administering to the animal a composition comprising:

(a) at least one aminoalkyl glucosaminide phosphate (AGP); and

(b) at least one saponin selected from QS-21 ~~, Quil A,~~ and QS-7~~, QS-17, QS-18~~, or a combination thereof;

wherein the AGP comprises a compound having the structure:



(I)

and pharmaceutically acceptable salts and derivatives thereof, wherein Y is –O-; R^1 and R^2 are each independently selected from saturated and unsaturated $(C_{10}$-$C_{14})$aliphatic acyl groups; R^8 is $P(O)(OH)_2$; R^9 is –H; and X is



(Ia)

wherein the subscripts m and q are 0 and n and p are 0, 1, or 2; R^3 is a saturated or unsaturated optionally substituted aliphatic $(C_{10}$-$C_{14})$acyl group; R^4 and R^5 are independently selected from H and methyl; R^6 is selected from H, OH and COOH, provided that the stereochemistry of the carbon atom to which R_5 is attached is not R when R_6 is OH or COOH; R^7 is H; and Z is –O.

92. (Canceled)

93. (Canceled)

94. (Currently Amended) A method of enhancing a CTL immune response in an animal to an antigen which comprises administering to the animal a composition comprising:

(a) at least one aminoalkyl glucosaminide phosphate (AGP); and

(b) at least one saponin selected from QS-21, ~~Quil A,~~ and QS-7, ~~QS-17, QS-18~~, or a combination thereof;

in combination with an antigen, wherein the AGP comprises a compound having the structure:



(I)

and pharmaceutically acceptable salts and derivatives thereof, wherein Y is –O-; R^1 and R^2 are each independently selected from saturated and unsaturated $(C_{10}$-$C_{14})$aliphatic acyl groups; R^8 is $P(O)(OH)_2$; R^9 is –H; and X is÷



(Ia)

wherein the subscripts m and q are 0 and n and p are 0, 1, or 2; R^3 is a saturated or unsaturated optionally substituted aliphatic (C_{10}-C_{14})acyl group; R^4 and R^5 are independently selected from H and methyl; R^6 is selected from H, OH and COOH, provided that the stereochemistry of the carbon atom to which R_5 is attached is not R when R_6 is OH or COOH; R^7 is H and Z is –O-.

95. (Canceled)

96. (Withdrawn) A method according to claim 91 in which R_1, R_2 and R_3 are each saturated C_{12} acyl; n is 0; p is 1; and R_6 is OH.

97. (Withdrawn) A method according to claim 91 in which R_1, R_2 and R_3 are each saturated C_{10} acyl; n is 1; p is 1; and R_6 is OH.

98. (Withdrawn) A method according to claim 91 in which R_1, R_2 and R_3 are each saturated C_{10} acyl; n is 0; p is 0; and R_6 is COOH.

99. (Previously Presented) A method according to claim 91 in which R_1, R_2 and R_3 are each saturated C_{14} acyl; n is 0; p is 0; and R_6 is H.

100. (Withdrawn) A method according to claim 91 in which R_1, R_2 and R_3 are each saturated C_{12} acyl; n is 2; p is 0; and R_6 is H.

101. - 104. (Canceled)

105. (Previously Presented) A method according to claim 91 in which the composition is an aqueous composition.

106. (Previously Presented) A method according to claim 105 in which the composition further comprises one or more surfactants.

107. (Previously Presented) A method according to claim 105 in which the composition further comprises one or more phospholipid surfactants.

108. (Withdrawn) A method according to claim 94 in which R_1, R_2 and R_3 are each saturated C_{12} acyl; n is 0; p is 1; and R_6 is OH.

109. (Withdrawn) A method according to claim 94 in which R_1, R_2 and R_3 are each saturated C_{10} acyl; n is 1; p is 1; and R_6 is OH.

110. (Withdrawn) A method according to claim 94 in which R_1, R_2 and R_3 are each saturated C_{10} acyl; n is 0; p is 0; and R_6 is COOH.

111. (Previously Presented) A method according to claim 94 in which R_1, R_2 and R_3 are each saturated C_{14} acyl; n is 0; p is 0; and R_6 is H.

112. (Withdrawn) A method according to claim 94 in which R_1, R_2 and R_3 are each saturated C_{12} acyl; n is 2; p is 0; and R_6 is H.

113. (Withdrawn) A method according to claim 94 in which the saponin is a Quillaja saponin.

114. (Canceled)

115. - 116. (Canceled)

117. (Previously Presented) A method according to claim 94 in which the composition is an aqueous composition.

118. (Previously Presented) A method according to claim 117 in which the composition further comprises one or more surfactants.

119. (Previously Presented) A method according to claim 117 in which the composition further comprises one or more phospholipid surfactants.

120. (Withdrawn) A method according to claim 94, wherein the antigen is derived from the group consisting of Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, HIV, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Tuberculosis, Leishmaniasis, T.Cruzi, Ehrlichia, Candida, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium and Toxoplasma.

121. (Previously Presented) A method according to claim 94, wherein the antigen is derived from tuberculosis.

122. (Withdrawn) A method according to claim 94, wherein the antigen is a human tumor antigen.

123. (Withdrawn) A method according to claim 122, wherein the tumor antigen is derived from a prostate, colon, breast, ovarian, pancreatic, brain, head and neck, melanoma, leukemia or lymphoma cancer.

124. (Withdrawn) A method according to claim 94, wherein the antigen is a self antigen.

125. (Withdrawn) A method according to claim 124, wherein the self antigen is an antigen associated with an autoimmune disease.

126. (Withdrawn) A method according to claim 125, wherein the autoimmune disease is type 1 diabetes, multiple sclerosis, myasthenia gravis, rheumatoid arthritis or psoriasis.

127. (New) A method according to claim 91, wherein the saponin is QS-21.

128. (New) A method according to claim 94, wherein the saponin is QS-21.